摘要
目的探讨乳腺癌肺转移患者的临床病理特点及预后因素。方法回顾性分析2000年1月至2007年1月天津医科大学附属肿瘤医院收治的119例乳腺癌肺转移患者的临床及随访资料。结果119例乳腺癌肺转移患者中，激素受体（hormone receptor，HR）＋／人表皮生长因子受体（human epithelial growth factor receptor，HER2）-、HR＋／HER2＋、HR-／HER2＋和三阴性乳腺癌（triple negative breast cancer，TNBC）各亚型所占比例分别为35．3％、17．6％、21．8％、25．2％，其中三阴性乳腺癌与其他亚型相比组织学分级Ⅲ级发生率较高（P=0．016）。本组患者的中位生存期为60个月（9—141个月），中位肺转移时间为29个月（3-99个月），发生肺转移后的中位生存期是33个月（6-98个月），1、2、3、5年生存率分别是72．9％、54．1％、35．1％和14．4％。结论三阴性乳腺癌、多发肺转移灶、肺转移时间≤24个月及是否曾接受系统化疗是影响肺转移患者预后的独立危险因素。
Objective To investigate the clinicopathological characteristics and prognosis of lung metastases from breast cancer. Methods The clinical data of 119 breast cancer patients treated at our institution from January 2000 to January 2007 were retrospectively reviewed. Results Among 119 patients with lung metastasis, 35.3% was hormone receptor （HR） ＋/human epithelial growth factor receptor （HER2） - , 17.6% was HR ＋/HER2 ＋ , 21.8% was HR -/HER2 ＋ and 25.2% was triple negative breast cancer （TNBC）. The rate of grade m in triple negative breast cancer was higher than the other subtypes（P =0. 016）. The median overall survival was 60 months （9 - 141 months） , the median time to lung metastases was 29 months （3 - 99 months ） , and the median survival after lung metastasis was 33 months （range, 6 -98 months）. The 1-,2-,3-and 5-year survival rate was 72. 9% ,54. 1% ,35.1% and 14. 4%. Conclusions TNBC, number of lung metastases, time to lung metastases less than 24 months, and a history of systemic chemotherapy were important factors for prognosis of patients with lung metastases.
出处
《中华普通外科杂志》
CSCD
北大核心
2013年第2期96-99,共4页
Chinese Journal of General Surgery
关键词
乳腺肿瘤
肿瘤转移
受体
预后
Breast neoplasms
Neoplasm metastasis
Receptors
Prognosis
